Lat­est news on thumbs down for Nu­plazid; Amy­lyx’s first ALS ap­proval; Buy­out buzz for trou­bled biotechs; Cannes Li­ons pre­view; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

It’s one con­fer­ence af­ter the oth­er in June. Now that #BIO22 is be­hind us, we’re shift­ing gears to Zach Bren­nan’s up­com­ing events at #DIA22 and on-the-ground cov­er­age from Cannes Li­ons by Beth Sny­der Bu­lik and Nicole De­Feud­is. If you’re tak­ing a long week­end like us — we’re off Mon­day in ob­ser­vance of June­teenth — I hope it’s just what you need.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.